Cargando…

Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

We evaluate differences in outcomes in younger (<65 years) and older (≥65 years) patients for target lesion failure (TLF) at 2-year follow-up in an unselected consecutive series of patients treated with the everolimus- (EES) and paclitaxel-eluting (PES) stents at a tertiary medical center. 348 co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shammas, Nicolas W., Shammas, Gail A., Sharis, Peter, Jerin, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683474/ https://www.ncbi.nlm.nih.gov/pubmed/23819051 http://dx.doi.org/10.1155/2013/471026

Ejemplares similares

Sex differences in long-term outcomes of coronary patients treated with drug-eluting stents at a tertiary medical center
por: Shammas, Nicolas W, et al.
Publicado: (2014)

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus eluting stent in a consecutive cohort of patients at a tertiary medical center
por: Shammas, Nicolas W, et al.
Publicado: (2012)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study
por: Shammas, Nicolas W, et al.
Publicado: (2015)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis
por: Wang, Zhi, et al.
Publicado: (2020)

Second Generation Drug-Eluting Stent Implantation versus Coronary Artery Bypass Grafting in the Treatment of Young Patients with Left Main and/or Multivessel Coronary Disease
por: Chen, Xue, et al.
Publicado: (2020)

Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses
por: Lee, Jong-Hyeog, et al.
Publicado: (2013)

Impact of Dual Antiplatelet Therapy with Proton Pump Inhibitors on the Outcome of Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation
por: Macaione, Francesca, et al.
Publicado: (2012)

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR
por: Wang, Zhongxia, et al.
Publicado: (2016)

The effectiveness and safety of the RESTORE(®) drug-eluting balloon versus a drug-eluting stent for small coronary vessel disease: study protocol for a multi-center, randomized, controlled trial
por: Tang, Yi–Da, et al.
Publicado: (2018)

Ten-year outcome of intraoperative treatment of atrial fibrillation using radiofrequency ablation
por: Boulad, Nour, et al.
Publicado: (2017)

Comparison between the Outcomes of Using Biodegradable-Polymer Drug-Eluting Stents and Those of Using Durable-Polymer Drug-Eluting Stents in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
por: Fawzy, Abd-Allah Y., et al.
Publicado: (2019)

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents
por: van der Heijden, Liefke C., et al.
Publicado: (2018)

Widowmaker Right Coronary Artery Treated With Drug-Eluting Stent Implantation
por: Singh, Gurpreet, et al.
Publicado: (2019)

“Burying” covered coronary stents under drug-eluting stents: A novel approach to ensure long-term stent patency
por: Bossard, Matthias, et al.
Publicado: (2023)

Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study
por: Matsuda, Hiroaki, et al.
Publicado: (2020)

Long-term effectiveness and safety of sirolimus drug-eluting stents
por: Bikkina, Mahesh, et al.
Publicado: (2011)

Long-term Clinical Outcomes of Drug-Eluting Stent Malapposition
por: Lee, Seung-Yul, et al.
Publicado: (2020)

Clinical Outcomes of Colonic Stent in a Tertiary Care Center
por: Gajendran, Mahesh, et al.
Publicado: (2014)

Value of M2BP in predicting in‐stent restenosis in patients after coronary drug‐eluting stent implantation
por: Yang, Le, et al.
Publicado: (2022)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease
por: Wada, Tadashi, et al.
Publicado: (2013)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Impact of the ultra‐long 48 mm drug‐eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease
por: Youn, Young Jin, et al.
Publicado: (2023)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Coronary artery perforation successfully treated with a second drug-eluting stent
por: Strycek, Matej, et al.
Publicado: (2023)

Long-term effect of stents eluting 6-mercaptopurine in porcine coronary arteries
por: Ruiter, Matthijs S., et al.
Publicado: (2016)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Long-term Outcomes of Drug-eluting Stents in Symptomatic Intracranial Stenosis
por: Park, Soonchan, et al.
Publicado: (2013)

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
por: Arroyo, Diego, et al.
Publicado: (2014)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
por: Xiu, Wen-Juan, et al.
Publicado: (2018)

Typical coronary artery aneurysm exactly within drug-eluting stent implantation region in a patient with rheumatoid arthritis
por: Zheng, Ying, et al.
Publicado: (2012)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Assessment of Time to Hospital Encounter after an Initial Hospitalization for Heart Failure: Results from a Tertiary Medical Center
por: Shammas, Nicolas W., et al.
Publicado: (2018)

Risk Factors for Long-term Outcome of Drug-eluting Stenting in Adults with Early-onset Coronary Artery Disease
por: An, Guipeng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3rlltqupbmhs64fc52nugme353